PEHRG 214
Alternative Names: PEHRG214Latest Information Update: 06 Mar 2019
At a glance
- Originator Virionyx
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 23 Apr 2009 Virionyx is now called Innate Therapeutics
- 31 Jan 2007 Phase-II clinical trials in HIV-1 infections in USA (IV-injection)
- 24 Aug 2005 Data presented at the 3rd IAS Conference on HIV Pathogenesis and Treatment (IAS-2005) have been added to the Viral infections antimicrobial activity section